Specific Central Memory T Cells in the Bone Marrow of Patients Immunized Against Tyrosinase Peptides
- 1 March 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 29 (2) , 201-207
- https://doi.org/10.1097/01.cji.0000180903.73965.72
Abstract
The goal of vaccination against tumors is the induction of effector T cells mediating tumor destruction and memory T cells providing long-term immunity. Several previous studies in patients vaccinated with major histocompatibility complex (MHC) class I peptides failed to show induction of central memory T cells, which are considered important to provide long-term memory. This study examined the subset composition and function of specific T cells generated by immunization with MHC class I binding tyrosinase peptides in combination with the adjuvants granulocyte-macrophage colony-stimulating factor and keyhole limpet hemocyanin in peripheral blood (PB) and bone marrow (BM) of melanoma patients. Most of the tyrosinase-specific T cells in PB had a CD45RA+CCR7− effector phenotype. In contrast to this, a large subset of tyrosinase-specific T cells in BM were memory T cells, including CD45RA−CCR7+ central and CD45RA−CCR7− effector memory T cells. BM tyrosinase-specific T cells were functional, because they produced interferon-γ and had a high proliferative potential. This study suggests that peptide vaccination can generate a fully functional memory T-cell response characterized by central and effector memory phenotypes, proliferative potential, and BM tropism.Keywords
This publication has 26 references indexed in Scilit:
- Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909Journal of Clinical Investigation, 2005
- Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV MelanomaJournal of Clinical Oncology, 2005
- Peptide vaccination after repeated resection of metastases can induce a prolonged relapse‐free interval in melanoma patientsInternational Journal of Cancer, 2005
- Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regressionProceedings of the National Academy of Sciences, 2004
- Cancer immunotherapy: moving beyond current vaccinesNature Medicine, 2004
- Central Memory and Effector Memory T Cell Subsets: Function, Generation, and MaintenanceAnnual Review of Immunology, 2004
- Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic CellsJournal of Clinical Oncology, 2003
- Effector and memory T-cell differentiation: implications for vaccine developmentNature Reviews Immunology, 2002
- Effects of Interleukin-12 on the Immune Response to a Multipeptide Vaccine for Resected Metastatic MelanomaJournal of Clinical Oncology, 2001
- Two subsets of memory T lymphocytes with distinct homing potentials and effector functionsNature, 1999